Expert panel backs continued use of 3 asthma drugs

An expert panel assembled by the FDA has recommended that three asthma drugs -- Advair, Serevent, and Foradil -- remain on the market with an adjustment in warning labels. The panel concluded that despite evidence that the drugs are linked to a small increase in the number of patient deaths, the benefits exceed the risks. The FDA will consider the recommendation and make a final ruling.

- read this report from KIDK TV for more